circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Muscle weakness can also be classified as either "proximal" or "distal" based on the location of the muscles that it affects. Proximal muscle weakness affects muscles closest to the body's midline, while distal muscle weakness affects muscles further out on the limbs. Proximal muscle weakness can be seen in Cushing's syndrome and hyperthyroidism.
Tel Yavne was first excavated in 2005 in a dig headed by Dan Bahat, who unearthed the gate room of the Crusader castle of Ibelin, as well as a vault destroyed with gunpowder by the Mamluks and deeply embedded Crusader walls east of it, all at or around the top of the tell. In December 2019, a large number of pottery kilns and 1,200-year-old gold coins which may have been a local potter's "piggy bank" were unearthed in a juglet by the Israel Antiquities Authority. According to archaeologist Robert Kool, the coins date back to the early Abbasid period, about 9th century CE. One of the seven coins was minted by Caliph Harun al-Rashid (786–809 CE). "These are gold dinars issued by the Aghlabid dynasty that ruled in North Africa. Without a doubt this is a wonderful Hanukkah present for us," said Kool. In August 2020, Israeli archaeologists discovered 425 complete gold coins, most dating to the Abbasid period around 1,100 years ago. In April 2021, archaeologists announced the discovery of a 1,600-year-old multicolored mosaic dated back to the Byzantine period in an industrial area. According to IAA archaeologist Elie Haddad, it was the first time that excavators revealed a colored mosaic floor in Yavne. The ancient harbour of Yavne, Yavne-Yam (in Arabic Minet Rubin) was identified on the coast. Excavations have revealed fortification going back to the Bronze Age Hyksos. It was in use from the Middle Bronze Age until the 12th century CE, when it was abandoned.
== Examples == Some examples of conjugated proteins are lipoproteins, glycoproteins, nucleoproteins, phosphoproteins, hemoproteins, flavoproteins, metalloproteins, phytochromes, cytochromes, opsins, and chromoproteins.
In another study, the combination of positively charged peptide amphiphiles and negatively charged long biopolymers led to the formation of hierarchically ordered membranes. When the two solutions are brought into contact, electrostatic complexation between the components of each solution creates a diffusion barrier that prevents the mixing of the solutions. Over time, an osmotic pressure difference drives the reptation of polymer chains through the diffusion barrier into the peptide amphiphile compartment, leading to the formation of fibers perpendicular to the interface that grow over time. These materials can be made in the form of flat membranes or as spherical sacs by dropping one solution into the other. These materials are robust enough to handle mechanically and a range of mechanical properties can be accessed by altering growth conditions and time. They can incorporate bioactive peptide amphiphiles, encapsulate cells and biomolecules, and are biocompatible and biodegradable.
Sources: en.wikipedia.org
Several types of chocolate can be distinguished. Pure, unsweetened chocolate, often called "baking chocolate", contains primarily non-fat cocoa solids and cocoa butter in varying proportions. Much of the chocolate consumed today is in the form of sweet chocolate, which combines chocolate with sugar.
==== Biomarkers of a whole grain diet ==== Increasing evidence from human intervention trials suggests that they are the most promising biomarker of whole grain wheat and rye intake. Alkylresorcinol metabolites, 3,5-dihydroxybenzoic acid (DHBA) and 3,5-dihydroxyphenylpropionoic acid (DHPPA) were first identified in urine and can be quantified in urine and plasma, and may be an alternative, equivalent biomarker of whole grain wheat intake. The average intake of alkylresorcinols in the UK is around 11 mg/person/day, and in Sweden is around 20 mg/person/day. This varies widely depending on whether people normally consume wholegrain/wholemeal/brown bread, which is high in alkylresorcinols (300-1000 μg/g), or white wheat bread, which has very low concentrations of alkylresorcinols (<50 μg/g).
=== Effect of nutrition === Nutritional status of an individual can be a crucial factor in the progression and healing of periodontal tissues. The relationship between oral health and systemic health has become an increasingly important subject. Studies have suggested that vitamins D and C in particular have a certain grade of relationship with periodontal health. However, the supplementation of vitamins is not enough to reverse the periodontium to a healthy state and that further research is needed to confirm theories. For example, scurvy is a disease resulting from a severe deficiency of vitamin C (ascorbic acid). Vitamin C is essential for the synthesis of collagen fibers.
Sources: en.wikipedia.org
In 1957, Marvin Margoshes and Bert L. Vallee at Harvard Medical School discovered that in horse kidney cortex, cadmium and zinc levels appeared to be maintained by binding to another molecule which they identified as a protein. They reported in the Journal of the American Chemical Society, concluding:The low sedimentation constant and high metal content of this material are indicative of a low molecular weight protein, probably containing a small number of cadmium atoms per molecule. Characterization of this unusual natural product is in progress.In 1958, Vallee presented the discovery at the International Congress of Biochemistry held in Vienna, and suggested that cadmium must be a natural biomolecule using the unknown protein. He pursued the research with his student Jeremias H. R. Kägi and was able to identify the new protein in 1960. The conclusion in The Journal of Biological Chemistry runs:The present study reports the isolation and characterization of a protein from equine renal cortex which contains 2.9% of cadmium, 0.6% of zinc, and 4.1% of sulfur per g dry weight of protein. This protein has been termed metallothionein in view of its metal and sulfur content.Vallee and Kägi reported further confirmation in the same journal in 1961. They later realised that metallothionein was not a single type of protein. With their collaborators, they could differentiate another related protein but with different amino acid properties and gave the name "metallothionein-1B" in 1970.
Southern Rhodesia had long been distinctive among British dependencies in that it had financed and developed its own security forces and command structure. After UDI, this posed a particular dilemma for the British government, which considered and rejected various proposals aimed at ending Rhodesia's state of rebellion by force. Harold Wilson once remarked that bringing an end to Rhodesian independence "would not be a case of arresting a subversive individual. It would mean a bloody war, and probably a bloody war turning into a bloody civil war." The formidable nature of the Rhodesian security forces, as well as British fears of a direct South African intervention on behalf of the rogue colony, preempted the further consideration of military options. For much of its existence, Rhodesia maintained a small professional standing army of 3,400 troops, about a third of whom were black volunteers. In the tradition of many colonial armies, it was primarily organised into light infantry battalions trained and equipped for counter-insurgency warfare or internal security actions, and possessed little artillery or armour. The Royal Rhodesian Air Force (RRAF) had 1,000 personnel and six squadrons of aircraft, including forty to fifty Hawker Hunter and de Havilland Vampire strike aircraft and English Electric Canberra light bombers. It also possessed a helicopter squadron, a transport squadron, and a light reconnaissance squadron.
==== MeSH D12.776.556.579.374 – nonheme iron proteins ==== MeSH D12.776.556.579.374.187 – hemerythrin MeSH D12.776.556.579.374.281 – inositol oxygenase MeSH D12.776.556.579.374.375 – iron-sulfur proteins MeSH D12.776.556.579.374.375.025 – adrenodoxin MeSH D12.776.556.579.374.375.150 – ferredoxin-nitrite reductase MeSH D12.776.556.579.374.375.275 – ferredoxins MeSH D12.776.556.579.374.375.275.450 – molybdoferredoxin MeSH D12.776.556.579.374.375.275.725 – rubredoxins MeSH D12.776.556.579.374.375.637 – iron regulatory protein 1 MeSH D12.776.556.579.374.375.818 – iron regulatory protein 2 MeSH D12.776.556.579.374.375.863 – electron transport complex i MeSH D12.776.556.579.374.375.863.500 – nadh dehydrogenase MeSH D12.776.556.579.374.375.909 – electron transport complex ii MeSH D12.776.556.579.374.375.909.500 – succinate dehydrogenase MeSH D12.776.556.579.374.375.954 – electron transport complex iii MeSH D12.776.556.579.374.375.977 – nitrate reductase (nad(p)h) MeSH D12.776.556.579.374.375.988 – nitrate reductase (nadph) MeSH D12.776.556.579.374.450 – lipoxygenase MeSH D12.776.556.579.374.450.025 – arachidonate lipoxygenases MeSH D12.776.556.579.374.450.025.020 – arachidonate 5-lipoxygenase MeSH D12.776.556.579.374.450.025.025 – arachidonate 12-lipoxygenase MeSH D12.776.556.579.374.450.025.030 – arachidonate 15-lipoxygenase MeSH D12.776.556.579.374.687 – retinal dehydrogenase MeSH D12.776.556.579.374.925 – tyrosine 3-monooxygenase
== Veterinary use == Fentanyl is commonly used for analgesia and as a component of balanced sedation and general anesthesia in small animal patients. The short-acting nature, wide safety profile, lower rate of adverse effect compared to other opioids, and high potency make fentanyl one of the most effective and common analgesics in veterinary medicine; the ability to reduce the minimum alveolar concentration leads to fentanyl being commonly used in dogs that are elderly or have cardiovascular issues. Due to its short duration and quick onset, fentanyl is commonly used as a constant rate infusion or as a transdermal patch, with the latter being able to last 3 to 4 days. Fentanyl can provide sedation for dogs. Fentanyl is less common and has more adverse effects in livestock and equine compared to cats and dogs. In horses at analgesic doses tachycardia, restlessness, and excitement occur. Subcutaneous administration often causes pain, but a bicarbonate solution exists which does not cause pain when given subcutaneously. Fentanyl is highly lipophilic, about 1000 times more than morphine. In dogs it has low protein binding of 15.6% and a half-life of 2–6 hours. In cats the half-life is 2.5 hours. Fentanyl has poor oral bio-availability due to it being metabolized by the liver. Transdermal and transmucosal formulations are common for out-patients, although the latter's efficacy is not well supported by evidence.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.